Patients gave blood serum samples prior to the treatment in 1992 and one year later in 1993. They were immunoassayed for specific IgE antibodies using a chemi-luminescent technique. Statistician Bradley Rosebrook ran T-Tests comparing average baseline IgE levels to one-year. For the seasonal allergens reported, the active group (n=34) had on average a greater reduction in IgE than the placebo group (n=33).7 On August 14, 1996 representatives products and for of Broncorp, Inc. met with the Division Director, Dr. John Jenkins, and 14 other FDA officials of the Pulmonary Division at a PreNDA meeting. Dr. Mansfield made a presentation on the 1995 study data (n=165) from Oregon, Washington and Idaho. He noted that together the data failed to show statistical superiority of vitamin B12 on the liver primary endpoint. He noted that in Washington and Idaho, during disorders the later part of the study, there was a drop in the pollen counts and marked improvements in symptoms in both the vitamin B12 and placebo groups. (This made a therapeutic products benefit of the B12 treatment difficult to demonstrate.) But that the pollen counts in Oregon remained higher throughout for the study and that the data from Oregon showed a significant difference between the active and placebo groups.8

In January 1997, 62 subjects who had been the placebos in the 1995 study were invited to receive the vitamin B12. In June 1997, the 62 placebo subjects were sent a questionnaire asking: How would you compare your overall allergy liver (hay fever) symptoms this spring to the last two springs? 20 people disorders and products responded, with 15 reporting having had the B12 treatment, and 5 not. 12 of the 15 reported at least a slight improvement in overall allergy symptoms, and 1 of the for 5. Improvement ratios - 12:3 having received treatment, 1:4 not having received treatment.8 A bioequivalence study showed that a 3000 mcg lozenge liver delivered an equivalent amount of cyanocobalamin to the blood as a 15 mcg injection.9 From the spring to the summer patients with demonstrated allergic rhinitis received with the cyanocobalamin disorders (or placebo) containing lozenge twice daily for 21 consecutive products days. All subjects also received C and B oral multivitamins for 21 days. Twice daily subjects maintained a nine-week diary on sneezing, runny nose, nasal congestion, itchy eyes, itchy nose and antihistamine (chlorpheniramine) use. In the post-treatment period, for the active group (n=15) recorded on average a greater reduction in symptoms and in antihistamine use than the placebo group (n=9). The results yielded reductions (0.1>p>0.01) in total weekly symptom/rescue medication for the active group liver compared to the placebo for weeks 2, 6, 8 and 9. The disorders results products and for tend to replicate those of the studies on injectable cyanocobalamin.10

A recent liver study in Japan indicates disorders that B12 treatment helps in the growth and division of certain immune system cells.11 products These cells function to prevent the immune system from for over-reacting to allergens such liver as animals, mold, dust, and disorders pollen. They are called suppressor products cells or CD8+ lymphocytes. They “put the brakes on the immune system”. this medicationTM is a 21-day treatment of B12 lozenges sucked on twice daily. this medicationTM may help patients for with hay fever by providing the patient’s suppressor cells with the sustained and elevated liver blood B12 level they need to grow and divide. It appears that by disorders helping the immune products system to become for what it is genetically capable of becoming, this medicationTM turns liver at least some allergic people into non-allergic or moderately-allergic disorders people.